Refractive implant guidance
This article was originally published in The Gray Sheet
Executive Summary
Comments on FDA's draft guidance on IDE and PMA submissions for refractive implants are due by Oct. 30. Released Aug. 1, the document applies to "any ocular implant whose primary indication is the modification of the refractive power of a phakic eye to improve distance and/or near uncorrected visual acuity [and] any intraocular lens intended for clear lens exchange." The draft notes that sponsors that pursue clear lens exchange as a refractive indication should be aware that FDA may recommend additional safety and efficacy endpoints. Members of FDA's Ophthalmic Devices Advisory Panel noted at a May 12 meeting that clear lens exchange holds an increased risk for retinal detachment. They also expressed anxiety over including phakic IOL implementation and IOL clear lens exchange procedures in the same guidance since the risk/benefit ratio and possible rates of adverse events were different for each procedure
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.